Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful » 08:08
06/03/20
06/03
08:08
06/03/20
08:08
GMAB

Genmab

$29.79 /

-1.01 (-3.28%)

, NVS

Novartis

$86.41 /

-0.26 (-0.30%)

Genmab's (GMAB)…

Genmab's (GMAB) partner Novartis (NVS) announced yesterday that the Prescription Drug User Fee Act approval decision date on ofatumumab for treatment of relapsing-remitting multiple sclerosis had been pushed back three months to September 20, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. Since the analyst always assumed that royalty-based revenues from ofatumumab sales in the U.S. would only begin accruing to Genmab starting in early 2021, he does not view the delay as impactful and is not making any changes to forecasts. Selvaraju, who notes that Novartis continues to expect ofatumumab approval for the MS indication in Europe during Q2 of 2021, reiterates a Buy rating on Genmab with a $34 price target.

ShowHide Related Items >><<
NVS Novartis
$86.41 /

-0.26 (-0.30%)

GMAB Genmab
$29.79 /

-1.01 (-3.28%)

GMAB Genmab
$29.79 /

-1.01 (-3.28%)

05:23 Today Bryan Garnier
Genmab downgraded to Neutral from Buy at Bryan Garnier
06/02/20 SunTrust
Genmab price target raised to $36 from $30 at SunTrust
06/02/20 Danske Bank
Genmab downgraded to Hold from Buy at Danske Bank
06/01/20 H.C. Wainwright
Genmab price target raised to $34 from $29 at H.C. Wainwright
NVS Novartis
$86.41 /

-0.26 (-0.30%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
NVS Novartis
$86.41 /

-0.26 (-0.30%)

GMAB Genmab
$29.79 /

-1.01 (-3.28%)

NVS Novartis
$86.41 /

-0.26 (-0.30%)

NVS Novartis
$86.41 /

-0.26 (-0.30%)

NVS Novartis
$86.41 /

-0.26 (-0.30%)

Yesterday
Hot Stocks
Novartis reports FDA has extended review of sBLA for ofatumumab » 16:14
06/02/20
06/02
16:14
06/02/20
16:14
NVS

Novartis

$86.35 /

-0.32 (-0.37%)

Novartis announced that…

Novartis announced that it has received notice from the U.S. Food and Drug Administration that the agency has extended its review of the Supplemental Biologics License Application, or sBLA, for ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. Regulatory action is now expected in September 2020. Additional regulatory filings are currently underway and regulatory approval for ofatumumab in Europe is expected by Q2 2021, the company said. "Novartis will continue to work with the FDA to complete the review as soon as possible. We are well prepared and ready to launch ofatumumab upon approval. We are committed to the MS community and look forward to bringing this important advancement to patients with MS," said Marie-France Tschudin, President, Novartis Pharmaceuticals.

ShowHide Related Items >><<
NVS Novartis
$86.35 /

-0.32 (-0.37%)

NVS Novartis
$86.35 /

-0.32 (-0.37%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
NVS Novartis
$86.35 /

-0.32 (-0.37%)

NVS Novartis
$86.35 /

-0.32 (-0.37%)

NVS Novartis
$86.35 /

-0.32 (-0.37%)

NVS Novartis
$86.35 /

-0.32 (-0.37%)

Friday
Conference/Events
Jefferies to hold a virtual conference » 10:17
05/29/20
05/29
10:17
05/29/20
10:17
BUD

AB InBev

$46.60 /

-0.8 (-1.69%)

, CMPGY

Compass Group

$0.00 /

+ (+0.00%)

, ERFSF

Eurofins Scientific

$0.00 /

+ (+0.00%)

, FMS

Fresenius Medical

$41.95 /

+0.41 (+0.99%)

, HSBC

HSBC

$23.01 /

-0.6 (-2.54%)

, IHG

InterContinental

$48.01 /

-1.045 (-2.13%)

, NSRGY

Nestle

$0.00 /

+ (+0.00%)

, NVS

Novartis

$86.99 /

+0.7 (+0.81%)

, RIO

Rio Tinto

$53.14 /

+0.62 (+1.18%)

, RTOKY

Rentokil

$0.00 /

+ (+0.00%)

, TSCDY

Tesco

$0.00 /

+ (+0.00%)

, UL

Unilever

$54.28 /

+0.66 (+1.23%)

, UN

Unilever

$51.57 /

+0.76 (+1.50%)

Virtual Structural…

Virtual Structural Winners Conference will be held on May 29. Webcast Link

ShowHide Related Items >><<
UL Unilever
$54.28 /

+0.66 (+1.23%)

RIO Rio Tinto
$53.14 /

+0.62 (+1.18%)

NVS Novartis
$86.99 /

+0.7 (+0.81%)

NSRGY Nestle
$0.00 /

+ (+0.00%)

IHG InterContinental
$48.01 /

-1.045 (-2.13%)

HSBC HSBC
$23.01 /

-0.6 (-2.54%)

FMS Fresenius Medical
$41.95 /

+0.41 (+0.99%)

CMPGY Compass Group
$0.00 /

+ (+0.00%)

BUD AB InBev
$46.60 /

-0.8 (-1.69%)

BUD AB InBev
$46.60 /

-0.8 (-1.69%)

05/20/20 JPMorgan
AB InBev upgraded to Neutral from Underweight at JPMorgan
05/13/20 Morgan Stanley
AB InBev price target lowered to EUR 39 from EUR 40 at Morgan Stanley
04/20/20 Morgan Stanley
AB InBev downgraded to Equal Weight from Overweight at Morgan Stanley
04/13/20 Evercore ISI
Beer production not resuming in Mexico, says Evercore ISI
CMPGY Compass Group
$0.00 /

+ (+0.00%)

05/22/20 UBS
Compass Group price target lowered to 1,585 GBp from 1,705 GBp at UBS
05/21/20 Barclays
Compass Group price target lowered to 1,050 GBp from 1,250 GBp at Barclays
05/21/20 Citi
Compass Group price target lowered to 1,280 GBp from 1,520 GBp at Citi
05/20/20 JPMorgan
Compass Group price target lowered to 1,050 GBp from 1,150 GBp at JPMorgan
ERFSF Eurofins Scientific
$0.00 /

+ (+0.00%)

05/27/20 Jefferies
Eurofins Scientific upgraded to Buy from Hold at Jefferies
03/11/20 Morgan Stanley
Eurofins Scientific upgraded to Equal Weight from Underweight at Morgan Stanley
02/14/20 Deutsche Bank
Eurofins Scientific initiated with a Sell at Deutsche Bank
01/16/20 Exane BNP Paribas
Eurofins downgraded to Underperform from Neutral at Exane BNP Paribas
FMS Fresenius Medical
$41.95 /

+0.41 (+0.99%)

05/20/20
Fly Intel: Top five analyst upgrades
05/20/20 Morgan Stanley
Fresenius Medical upgraded to Equal Weight from Underweight at Morgan Stanley
05/19/20 JPMorgan
Fresenius Medical price target lowered to EUR 84.20 from EUR 90.80 at JPMorgan
05/14/20 Kepler Cheuvreux
Fresenius Medical upgraded to Buy from Hold at Kepler Cheuvreux
HSBC HSBC
$23.01 /

-0.6 (-2.54%)

05/14/20 Berenberg
HSBC upgraded to Hold from Sell at Berenberg
05/12/20 RBC Capital
HSBC price target lowered to 410 GBp from 440 GBp at RBC Capital
05/05/20 Barclays
HSBC price target lowered to 410 GBp from 420 GBp at Barclays
04/29/20 UBS
HSBC price target lowered to 405 GBp from 450 GBp at UBS
IHG InterContinental
$48.01 /

-1.045 (-2.13%)

05/18/20 Goldman Sachs
Accor downgraded to Sell from Buy at Goldman Sachs
05/11/20 Kepler Cheuvreux
InterContinental upgraded to Hold from Reduce at Kepler Cheuvreux
05/04/20 Deutsche Bank
InterContinental price target lowered to 4,300 GBp at Deutsche Bank
04/17/20 Barclays
InterContinental upgraded to Overweight from Underweight at Barclays
NSRGY Nestle
$0.00 /

+ (+0.00%)

05/05/20 JPMorgan
Nestle price target raised to CHF 116 from CHF 99 at JPMorgan
04/29/20 UBS
Nestle price target raised to CHF 114 from CHF 105 at UBS
04/28/20 RBC Capital
Nestle price target raised to CHF 79 from CHF 75 at RBC Capital
04/27/20 Barclays
Nestle price target raised to CHF 112 from CHF 105 at Barclays
NVS Novartis
$86.99 /

+0.7 (+0.81%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
RIO Rio Tinto
$53.14 /

+0.62 (+1.18%)

05/29/20 BofA
Rio Tinto upgraded to Buy from Neutral at BofA
05/26/20 Morgan Stanley
Rio Tinto price target lowered to 4,300 GBp from 4,400 GBp at Morgan Stanley
05/22/20 Jefferies
Jefferies adds six names to Franchise Picks list, including BioMarin and TJX
05/20/20 UBS
Rio Tinto price target lowered to 4,100 GBp from 4,250 GBp at UBS
RTOKY Rentokil
$0.00 /

+ (+0.00%)

05/04/20 Morgan Stanley
Rentokil initiated with an Overweight at Morgan Stanley
04/17/20 Credit Suisse
Rentokil price target raised to 390 GBp from 360 GBp at Credit Suisse
04/01/20 Deutsche Bank
Rentokil price target lowered to 390 GBp from 460 GBp at Deutsche Bank
03/26/20 JPMorgan
Rentokil downgraded to Neutral from Overweight at JPMorgan
TSCDY Tesco
$0.00 /

+ (+0.00%)

04/28/20 Berenberg
Tesco price target lowered to 275 GBp from 280 GBp at Berenberg
03/30/20 Credit Suisse
Tesco upgraded to Neutral from Underperform at Credit Suisse
03/24/20 HSBC
Tesco upgraded to Buy from Hold at HSBC
02/27/20 Credit Suisse
Tesco initiated with an Underperform at Credit Suisse
UL Unilever
$54.28 /

+0.66 (+1.23%)

05/04/20 JPMorgan
Unilever price target raised to 4,300 GBp from 3,850 GBp at JPMorgan
04/28/20 DZ Bank
Unilever downgraded to Hold from Buy at DZ Bank
04/15/20 Credit Suisse
Unilever price target lowered to EUR 54 from EUR 56.50 at Credit Suisse
04/08/20 HSBC
Unilever upgraded to Hold from Reduce at HSBC
UN Unilever
$51.57 /

+0.76 (+1.50%)

05/04/20 JPMorgan
Unilever NV price target raised to EUR 48 from EUR 42 at JPMorgan
04/07/20 Morgan Stanley
Unilever double downgraded to Underweight at Morgan Stanley
UL Unilever
$54.28 /

+0.66 (+1.23%)

NVS Novartis
$86.99 /

+0.7 (+0.81%)

NSRGY Nestle
$0.00 /

+ (+0.00%)

HSBC HSBC
$23.01 /

-0.6 (-2.54%)

FMS Fresenius Medical
$41.95 /

+0.41 (+0.99%)

BUD AB InBev
$46.60 /

-0.8 (-1.69%)

UL Unilever
$54.28 /

+0.66 (+1.23%)

TSCDY Tesco
$0.00 /

+ (+0.00%)

RIO Rio Tinto
$53.14 /

+0.62 (+1.18%)

NVS Novartis
$86.99 /

+0.7 (+0.81%)

NSRGY Nestle
$0.00 /

+ (+0.00%)

IHG InterContinental
$48.01 /

-1.045 (-2.13%)

HSBC HSBC
$23.01 /

-0.6 (-2.54%)

CMPGY Compass Group
$0.00 /

+ (+0.00%)

BUD AB InBev
$46.60 /

-0.8 (-1.69%)

RIO Rio Tinto
$53.14 /

+0.62 (+1.18%)

NVS Novartis
$86.99 /

+0.7 (+0.81%)

NSRGY Nestle
$0.00 /

+ (+0.00%)

IHG InterContinental
$48.01 /

-1.045 (-2.13%)

HSBC HSBC
$23.01 /

-0.6 (-2.54%)

BUD AB InBev
$46.60 /

-0.8 (-1.69%)

RIO Rio Tinto
$53.14 /

+0.62 (+1.18%)

NVS Novartis
$86.99 /

+0.7 (+0.81%)

HSBC HSBC
$23.01 /

-0.6 (-2.54%)

BUD AB InBev
$46.60 /

-0.8 (-1.69%)

Thursday
Hot Stocks
Novartis to manufacture COVID vaccine program from Massachusetts General » 08:45
05/28/20
05/28
08:45
05/28/20
08:45
NVS

Novartis

$84.49 /

-0.475 (-0.56%)

The AAVCOVID vaccine…

The AAVCOVID vaccine program at Massachusetts Eye and Ear and Massachusetts General Hospital has entered into a manufacturing agreement to produce its novel genetic vaccine with an industry leader in gene therapy, AveXis, a Novartis Company. AveXis will begin manufacturing the vaccine this month while AAVCOVID undergoes further safety and efficacy testing in preclinical studies taking place at academic medical institutions including Mass. Eye and Ear. Through the strategic partnership, AveXis is "contributing its technology, expertise and supply chain at no cost to supply the AAV vaccine for COVID clinical trials scheduled to begin in the second half of 2020." Reference Link

ShowHide Related Items >><<
NVS Novartis
$84.49 /

-0.475 (-0.56%)

NVS Novartis
$84.49 /

-0.475 (-0.56%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
NVS Novartis
$84.49 /

-0.475 (-0.56%)

NVS Novartis
$84.49 /

-0.475 (-0.56%)

NVS Novartis
$84.49 /

-0.475 (-0.56%)

NVS Novartis
$84.49 /

-0.475 (-0.56%)

Over a week ago
Periodicals
WHO's hydroxychloroquine trial suspended pending safety data, Bloomberg says » 18:00
05/25/20
05/25
18:00
05/25/20
18:00
MYL

Mylan

$15.63 /

-0.37 (-2.31%)

, TEVA

Teva

$11.97 /

-0.05 (-0.42%)

, NVS

Novartis

$84.84 /

-0.12 (-0.14%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

The World Health…

The World Health Organization temporarily halted tests on hydroxychloroquine in its COVID-19 drug trials pending more data because of safety concerns, Bloomberg's Corinne Gretler reports. The steering committee decided to suspend enrollment to that arm of the so-called Solidarity trials, WHO officials said Monday. That's after the Lancet published a study that said the drug, touted by U.S. President Donald Trump as a treatment, was linked to an increased risk of death and heart ailments, the author notes. Mylan (MYL), Teva (TEVA), Novartis (NVS), and Bayer (BAYRY) are among companies that had announced efforts to increase hydroxychloroquine production early in the COVID-19 outbreak. Reference Link

ShowHide Related Items >><<
TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
TEVA Teva
$11.97 /

-0.05 (-0.42%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
NVS Novartis
$84.84 /

-0.12 (-0.14%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
BAYRY Bayer
$0.00 /

+ (+0.00%)

04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

On The Fly
Week in Review: How Trump's policies moved stocks » 09:55
05/23/20
05/23
09:55
05/23/20
09:55
AZN

AstraZeneca

$55.21 /

-0.04 (-0.07%)

, MRNA

Moderna

$69.00 /

+1.99 (+2.97%)

, JNJ

Johnson & Johnson

$144.37 /

-0.29 (-0.20%)

, SNY

Sanofi

$47.31 /

-0.18 (-0.38%)

, MRK

Merck

$76.37 /

-0.17 (-0.22%)

, MYL

Mylan

$15.63 /

-0.37 (-2.31%)

, TEVA

Teva

$11.97 /

-0.05 (-0.42%)

, NVS

Novartis

$84.84 /

-0.12 (-0.14%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, LITE

Lumentum

$73.50 /

+1.74 (+2.42%)

, NPTN

NeoPhotonics

$8.31 /

+ (+0.00%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TEVA Teva
$11.97 /

-0.05 (-0.42%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

NPTN NeoPhotonics
$8.31 /

+ (+0.00%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

MRK Merck
$76.37 /

-0.17 (-0.22%)

LITE Lumentum
$73.50 /

+1.74 (+2.42%)

JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
05/01/20 Guggenheim
AstraZeneca price target raised to 9,100 GBp from 8,900 GBp at Guggenheim
MRNA Moderna
$69.00 /

+1.99 (+2.97%)

05/20/20 Morgan Stanley
Moderna price target raised to $90 from $37 at Morgan Stanley
05/19/20 Piper Sandler
Piper trims Moderna target to $100 on capital raise dilution
05/19/20 BMO Capital
Moderna price target raised to $112 from $83 at BMO Capital
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
04/28/20 UBS
Johnson & Johnson downgraded to Neutral from Buy at UBS
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

05/06/20 Oppenheimer
Regeneron price target raised to $625 from $525 at Oppenheimer
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
04/28/20 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
MRK Merck
$76.37 /

-0.17 (-0.22%)

05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
MYL Mylan
$15.63 /

-0.37 (-2.31%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
TEVA Teva
$11.97 /

-0.05 (-0.42%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
NVS Novartis
$84.84 /

-0.12 (-0.14%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
BAYRY Bayer
$0.00 /

+ (+0.00%)

04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
LITE Lumentum
$73.50 /

+1.74 (+2.42%)

05/21/20 Rosenblatt
Rosenblatt sees little impact on Lumentum, NeoPhotonics' current sales to Huawei
05/06/20 Craig-Hallum
Lumentum price target raised to $100 from $95 at Craig-Hallum
05/06/20 Piper Sandler
Lumentum price target raised to $100 from $95 at Piper Sandler
05/05/20 Raymond James
Lumentum price target raised to $97 from $90 at Raymond James
NPTN NeoPhotonics
$8.31 /

+ (+0.00%)

05/01/20 Northland
NeoPhotonics price target raised to $13 from $9.75 at Northland
05/01/20 Piper Sandler
NeoPhotonics price target raised to $14 from $9 at Piper Sandler
04/24/20 Rosenblatt
NeoPhotonics downgraded to Neutral at Rosenblatt with stock near three-year high
TEVA Teva
$11.97 /

-0.05 (-0.42%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

NPTN NeoPhotonics
$8.31 /

+ (+0.00%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

MRK Merck
$76.37 /

-0.17 (-0.22%)

LITE Lumentum
$73.50 /

+1.74 (+2.42%)

JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

  • 19
    May
TEVA Teva
$11.97 /

-0.05 (-0.42%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

MRK Merck
$76.37 /

-0.17 (-0.22%)

LITE Lumentum
$73.50 /

+1.74 (+2.42%)

JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

NPTN NeoPhotonics
$8.31 /

+ (+0.00%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

MRK Merck
$76.37 /

-0.17 (-0.22%)

LITE Lumentum
$73.50 /

+1.74 (+2.42%)

JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

MRK Merck
$76.37 /

-0.17 (-0.22%)

LITE Lumentum
$73.50 /

+1.74 (+2.42%)

JNJ Johnson & Johnson
$144.37 /

-0.29 (-0.20%)

AZN AstraZeneca
$55.21 /

-0.04 (-0.07%)

Periodicals
Hydroxychloroquine linked to higher death risk in COVID patients, WaPo reports » 08:41
05/22/20
05/22
08:41
05/22/20
08:41
MYL

Mylan

$16.00 /

-0.34 (-2.08%)

, TEVA

Teva

$12.02 /

+0.02 (+0.17%)

, NVS

Novartis

$84.96 /

-0.97 (-1.13%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

Hydroxychloroquine, the…

Hydroxychloroquine, the anti-malaria drug that President Trump has said that he has been taking to prevent himself from contracting coronavirus infection, has been linked to a significantly higher risk of death and patients taking it were also more likely to develop a type of irregular heart rhythm that can lead to sudden cardiac death, a study published in medical journal the Lancet concluded, reported The Washington Post's Ariana Eunjung Cha and Laurie McGinley. Mylan (MYL), Teva (TEVA), Novartis (NVS), and Bayer (BAYRY) are among companies that had announced efforts to increase hydroxychloroquine production early in the COVID-19 outbreak. Reference Link

ShowHide Related Items >><<
TEVA Teva
$12.02 /

+0.02 (+0.17%)

NVS Novartis
$84.96 /

-0.97 (-1.13%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
TEVA Teva
$12.02 /

+0.02 (+0.17%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
NVS Novartis
$84.96 /

-0.97 (-1.13%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
BAYRY Bayer
$0.00 /

+ (+0.00%)

04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
TEVA Teva
$12.02 /

+0.02 (+0.17%)

NVS Novartis
$84.96 /

-0.97 (-1.13%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$12.02 /

+0.02 (+0.17%)

NVS Novartis
$84.96 /

-0.97 (-1.13%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$12.02 /

+0.02 (+0.17%)

NVS Novartis
$84.96 /

-0.97 (-1.13%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$12.02 /

+0.02 (+0.17%)

NVS Novartis
$84.96 /

-0.97 (-1.13%)

MYL Mylan
$16.00 /

-0.34 (-2.08%)

Recommendations
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas » 17:11
05/18/20
05/18
17:11
05/18/20
17:11
RIO

Rio Tinto

$51.44 /

+3.845 (+8.08%)

, ASAZY

Assa Abloy

$0.00 /

+ (+0.00%)

, BZLYF

Beazley

$0.00 /

+ (+0.00%)

, FERGY

Ferguson

$0.00 /

+ (+0.00%)

, HAYPY

Hays

$0.00 /

+ (+0.00%)

, NVS

Novartis

$84.87 /

+0.89 (+1.06%)

, NGLOY

Anglo American

$0.00 /

+ (+0.00%)

, BP

BP

$23.49 /

+1.68 (+7.70%)

, PDRDY

Pernod Ricard

$0.00 /

+ (+0.00%)

, UCBJY

UCB

$0.00 /

+ (+0.00%)

Jefferies analyst Jerry…

Jefferies analyst Jerry Dellis amends the firm's Franchise Picks list to include Assa Abloy (ASAZY), Beazley (BZLYF), Ferguson (FERGY), Hays (HAYPY), Novartis (NVS) and Rio Tinto (RIO) while removing Anglo American (NGLOY), BP (BP), Pernod Ricard (PDRDY) and UCB (UCBJY). The analyst is positive on Assa Abloy's dominant franchise in access control, Beazley's "generational opportunity in cyber" as more people work from home, Ferguson's "consistent ability to grow ahead of market", Hays' "fortress balance sheet" ahead of investment-driven upturn, Novartis' undervalued late-stage pipeline optionality, and Rio Tinto's strong balance sheet / low cost asset base.

ShowHide Related Items >><<
UCBJY UCB
$0.00 /

+ (+0.00%)

RIO Rio Tinto
$51.44 /

+3.845 (+8.08%)

PDRDY Pernod Ricard
$0.00 /

+ (+0.00%)

NVS Novartis
$84.87 /

+0.89 (+1.06%)

NGLOY Anglo American
$0.00 /

+ (+0.00%)

BZLYF Beazley
$0.00 /

+ (+0.00%)

BP BP
$23.49 /

+1.68 (+7.70%)

ASAZY Assa Abloy
$0.00 /

+ (+0.00%)

RIO Rio Tinto
$51.44 /

+3.845 (+8.08%)

05/11/20 JPMorgan
Rio Tinto price target lowered to 4,560 GBp from 4,730 GBp at JPMorgan
04/30/20 JPMorgan
Rio Tinto price target lowered to 4,730 GBp from 4,870 GBp at JPMorgan
04/23/20 Societe Generale
Rio Tinto price target raised to 4,240 GBp from 4,100 GBp at Societe Generale
04/20/20 JPMorgan
Rio Tinto price target raised to 4,870 GBp from 4,860 GBp at JPMorgan
ASAZY Assa Abloy
$0.00 /

+ (+0.00%)

04/30/20 Morgan Stanley
Assa Abloy price target raised to SEK 189 from SEK 178 at Morgan Stanley
04/21/20 Jefferies
Assa Abloy upgraded to Buy from Hold at Jefferies
04/09/20 Deutsche Bank
Assa Abloy price target lowered to SEK 175 from SEK 180 at Deutsche Bank
04/01/20 Morgan Stanley
Assa Abloy price target lowered to SEK 178 from SEK 186 at Morgan Stanley
BZLYF Beazley
$0.00 /

+ (+0.00%)

05/15/20 Credit Suisse
Beazley initiated with a Neutral at Credit Suisse
05/14/20 Morgan Stanley
Beazley price target lowered to 505 GBp from 560 GBp at Morgan Stanley
05/07/20 JPMorgan
Beazley downgraded to Neutral from Overweight at JPMorgan
04/24/20 Jefferies
Beazley upgraded to Buy from Hold at Jefferies
FERGY Ferguson
$0.00 /

+ (+0.00%)

05/14/20 UBS
Ferguson price target raised to 7,250 GBp from 6,625 GBp at UBS
05/14/20 Societe Generale
Ferguson downgraded to Hold from Buy at Societe Generale
05/14/20 Societe Generale
Ferguson downgraded to Hold from Buy at Societe Generale
04/17/20 Credit Suisse
Ferguson upgraded to Neutral from Underperform at Credit Suisse
HAYPY Hays
$0.00 /

+ (+0.00%)

03/23/20 Morgan Stanley
Hays price target lowered to 110 GBp from 155 GBp at Morgan Stanley
03/16/20 Jefferies
Hays upgraded to Buy from Hold at Jefferies
NVS Novartis
$84.87 /

+0.89 (+1.06%)

05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
04/29/20 JPMorgan
Novartis price target lowered to CHF 84 from CHF 91 at JPMorgan
NGLOY Anglo American
$0.00 /

+ (+0.00%)

05/07/20 Credit Suisse
Anglo American upgraded to Outperform from Neutral at Credit Suisse
04/30/20 JPMorgan
Anglo American price target raised to 2,500 GBp from 2,300 GBp at JPMorgan
04/29/20 RBC Capital
Anglo American price target lowered to 1,450 GBp from 1,500 GBp at RBC Capital
04/27/20 Jefferies
Anglo American price target lowered to 1,700 GBp from 1,750 GBp at Jefferies
BP BP
$23.49 /

+1.68 (+7.70%)

05/15/20
Fly Intel: Top five analyst downgrades
05/15/20 Morgan Stanley
Morgan Stanley downgrades BP to Underweight, sees 50% dividend cut
05/14/20 Morgan Stanley
BP downgraded to Underweight from Equal Weight at Morgan Stanley
05/13/20 Redburn
BP upgraded to Buy from Neutral at Redburn
PDRDY Pernod Ricard
$0.00 /

+ (+0.00%)

05/18/20 Goldman Sachs
Remy Cointreau downgraded to Neutral from Buy at Goldman Sachs
04/24/20 Barclays
Pernod Ricard price target lowered to EUR 138 from EUR 144 at Barclays
04/24/20 RBC Capital
Pernod Ricard price target raised to EUR 122 from EUR 121 at RBC Capital
04/24/20 Credit Suisse
Pernod Ricard price target lowered to EUR 157 from EUR 190 at Credit Suisse
UCBJY UCB
$0.00 /

+ (+0.00%)

01/05/20 JPMorgan
UCB upgraded to Overweight from Neutral at JPMorgan
10/29/19 JPMorgan
UCB upgraded to Neutral from Underweight at JPMorgan
09/05/19 Barclays
UCB upgraded to Equal Weight from Underweight at Barclays
05/30/19 Goldman Sachs
UCB upgraded to Buy from Neutral at Goldman Sachs
NVS Novartis
$84.87 /

+0.89 (+1.06%)

BP BP
$23.49 /

+1.68 (+7.70%)

RIO Rio Tinto
$51.44 /

+3.845 (+8.08%)

NVS Novartis
$84.87 /

+0.89 (+1.06%)

BP BP
$23.49 /

+1.68 (+7.70%)

RIO Rio Tinto
$51.44 /

+3.845 (+8.08%)

NVS Novartis
$84.87 /

+0.89 (+1.06%)

BP BP
$23.49 /

+1.68 (+7.70%)

RIO Rio Tinto
$51.44 /

+3.845 (+8.08%)

NVS Novartis
$84.87 /

+0.89 (+1.06%)

BP BP
$23.49 /

+1.68 (+7.70%)

Periodicals
Trump taking hydroxychloroquine to prevent coronavirus infection, CNBC says » 16:56
05/18/20
05/18
16:56
05/18/20
16:56
MYL

Mylan

$16.46 /

+1.3 (+8.58%)

, NVS

Novartis

$84.87 /

+0.89 (+1.06%)

President Trump said …

President Trump said that he has been taking anti-malaria drug hydroxychloroquine fo more than a week to to prevent himself from contracting coronavirus infection, reports CNBC. The Fly notes that Mylan (MYL) and Novartis (NVS) are making chloroquine tablets to fight COVID-19. Reference Link

ShowHide Related Items >><<
NVS Novartis
$84.87 /

+0.89 (+1.06%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
NVS Novartis
$84.87 /

+0.89 (+1.06%)

05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
04/29/20 JPMorgan
Novartis price target lowered to CHF 84 from CHF 91 at JPMorgan
NVS Novartis
$84.87 /

+0.89 (+1.06%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

NVS Novartis
$84.87 /

+0.89 (+1.06%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

NVS Novartis
$84.87 /

+0.89 (+1.06%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

NVS Novartis
$84.87 /

+0.89 (+1.06%)

MYL Mylan
$16.46 /

+1.3 (+8.58%)

Conference/Events
Piper Sandler healthcare analysts to hold an analyst/industry conference call » 10:02
05/15/20
05/15
10:02
05/15/20
10:02
BHVN

Biohaven Pharmaceutical

$44.44 /

+0.19 (+0.43%)

, ABBV

AbbVie

$90.38 /

+0.38 (+0.42%)

, LLY

Eli Lilly

$157.46 /

-0.85 (-0.54%)

, ALDR

Alder Biopharmaceuticals

$18.92 /

+ (+0.00%)

, AMGN

Amgen

$234.90 /

-1.495 (-0.63%)

, NVS

Novartis

$84.29 /

+0.3 (+0.36%)

, TEVA

Teva

$11.03 /

+0.07 (+0.64%)

Healthcare Analysts…

Healthcare Analysts discuss the ongoing launches of oral Calcitonin Gene-Related Peptide (CGRPs) on an Analyst/Industry conference call to be held on May 15 at 11 am.

ShowHide Related Items >><<
TEVA Teva
$11.03 /

+0.07 (+0.64%)

NVS Novartis
$84.29 /

+0.3 (+0.36%)

LLY Eli Lilly
$157.46 /

-0.85 (-0.54%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

AMGN Amgen
$234.90 /

-1.495 (-0.63%)

ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

05/11/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $82 from $75 at Cantor Fitzgerald
04/17/20 Cowen
Cowen initiates Biohaven Pharmaceutical with Outperform on migraine opportunity
04/17/20 Cowen
Biohaven Pharmaceutical initiated with an Outperform at Cowen
03/31/20 Oppenheimer
Biohaven Pharmaceutical price target lowered to $37 from $48 at Oppenheimer
ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
05/11/20
Fly Intel: Top five analyst initiations
05/11/20 Morgan Stanley
AbbVie resumed with an Overweight at Morgan Stanley
05/01/20 Piper Sandler
Piper Sandler remains a buyer of 'resilient' AbbVie after earnings
LLY Eli Lilly
$157.46 /

-0.85 (-0.54%)

04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
ALDR Alder Biopharmaceuticals
$18.92 /

+ (+0.00%)

09/17/19
Fly Intel: Top five analyst upgrades
09/17/19 William Blair
William Blair reiterates Outperform on Biohaven after Alder buyout
09/17/19 Credit Suisse
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
09/17/19 UBS
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
AMGN Amgen
$234.90 /

-1.495 (-0.63%)

05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/04/20 Cantor Fitzgerald
Amgen price target raised to $263 from $255 at Cantor Fitzgerald
05/01/20 BMO Capital
Amgen price target raised to $291 from $274 at BMO Capital
05/01/20 Wells Fargo
Amgen price target raised to $237 from $220 at Wells Fargo
NVS Novartis
$84.29 /

+0.3 (+0.36%)

05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
04/29/20 JPMorgan
Novartis price target lowered to CHF 84 from CHF 91 at JPMorgan
TEVA Teva
$11.03 /

+0.07 (+0.64%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
TEVA Teva
$11.03 /

+0.07 (+0.64%)

NVS Novartis
$84.29 /

+0.3 (+0.36%)

LLY Eli Lilly
$157.46 /

-0.85 (-0.54%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

AMGN Amgen
$234.90 /

-1.495 (-0.63%)

ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

TEVA Teva
$11.03 /

+0.07 (+0.64%)

NVS Novartis
$84.29 /

+0.3 (+0.36%)

LLY Eli Lilly
$157.46 /

-0.85 (-0.54%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

AMGN Amgen
$234.90 /

-1.495 (-0.63%)

ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

TEVA Teva
$11.03 /

+0.07 (+0.64%)

NVS Novartis
$84.29 /

+0.3 (+0.36%)

LLY Eli Lilly
$157.46 /

-0.85 (-0.54%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

AMGN Amgen
$234.90 /

-1.495 (-0.63%)

ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

TEVA Teva
$11.03 /

+0.07 (+0.64%)

NVS Novartis
$84.29 /

+0.3 (+0.36%)

BHVN Biohaven Pharmaceutical
$44.44 /

+0.19 (+0.43%)

ABBV AbbVie
$90.38 /

+0.38 (+0.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.